IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
Provided By PR Newswire
Last update: Jun 23, 2025
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG
Read more at prnewswire.com152.41
+0.4 (+0.26%)
Find more stocks in the Stock Screener
JNJ Latest News and Analysis
11 days ago - ChartmillJohnson & Johnson (NYSE:JNJ) - A Reliable Dividend Stock Worth ConsideringJohnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors.
